COVID-19 유행 시기의 성인 염증성 장질환 임상 진료지침: 전문가 합의 권고문

• Published in: The Korean journal of gastroenterology Vol. 78; no. 2; pp. 105 - 116
• Main Authors: 박용은, Yong Eun Park, 이유진, Yoo Jin Lee, 장지영, Ji Young Chang, 송현주, Hyun Joo Song, 김덕환, Duk Hwan Kim, 양영주, Young Joo Yang, 김병창, Byung Chang Kim, 이재곤, Jae Gon Lee, 양희찬, Hee Chan Yang, 최미영, Miyoung Choi, 김성은, Seong-eun Kim, 명승재, Seung-jae Myung
• Format: Journal Article
• Language: Korean
• Published: 대한소화기학회 31.08.2021
• Subjects: COVID-19; Disease management; Inflammatory bowel diseases; SARS-CoV-2; 내과학
• ISSN: 1598-9992; 2233-6869
• DOI: 10.4166/kjg.2021.112

The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients. (Korean J Gastroenterol 2021;78:105-116)